Taken together, these data suggest that the combination of interferon, interleukin-2, and thalidomide reduces the level of MRD in hematological remission, aiding patients AML1-ETO fusion gene–positive AML in reaching negative or decreased MRD, showing a dose–response relationship. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.